Does Levalbuterol (Xopenex®) Live Up to the Hype?

Thumbnail Image

Persistent link to this item

View Statistics

Journal Title

Journal ISSN

Volume Title


Does Levalbuterol (Xopenex®) Live Up to the Hype?

Published Date






Asthma, in general, is a respiratory disorder that affects millions of Americans each year. Reasonably priced, effective treatments have been developed by several pharmacological companies designed to treat this condition by various mechanisms. Levalbuterol has recently been developed and marketed as a direct beta2 agonist with improved efficacy in symptom relief as well as an improved side effect profile. A direct superiority study comparing side effect profiles of both racemic albuterol and levalbuterol concluded that no significant improvement was noticed with respect to side effect profiles between the two medications.


The information provided in this handout does not necessarily reflect the views of the University of Minnesota Medical School physicians and faculty. These materials are provided for informational purposes only and are in no way intended to take the place of the advice and recommendations of your personal health care provider. You use the information provided in these handouts at your own risk.

Related to



Series/Report Number

Funding information

Isbn identifier

Doi identifier

Previously Published Citation

Suggested citation

Voge, Dylan. (2008). Does Levalbuterol (Xopenex®) Live Up to the Hype?. Retrieved from the University Digital Conservancy,

Content distributed via the University Digital Conservancy may be subject to additional license and use restrictions applied by the depositor. By using these files, users agree to the Terms of Use. Materials in the UDC may contain content that is disturbing and/or harmful. For more information, please see our statement on harmful content in digital repositories.